Innate Pharma (IPHA) Expected to Announce Quarterly Earnings on Thursday

Innate Pharma (NASDAQ:IPHA) is expected to issue its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.3492) per share and revenue of $1.96 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 26, 2026 at 9:00 AM ET.

Innate Pharma Stock Performance

IPHA stock opened at $1.26 on Wednesday. Innate Pharma has a 1-year low of $1.17 and a 1-year high of $2.63. The business has a fifty day moving average price of $1.65 and a 200-day moving average price of $1.82.

Wall Street Analysts Forecast Growth

IPHA has been the subject of several research analyst reports. BTIG Research assumed coverage on Innate Pharma in a report on Thursday, March 12th. They issued a “buy” rating and a $8.00 price objective for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Innate Pharma in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Innate Pharma has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Hedge Funds Weigh In On Innate Pharma

Several hedge funds and other institutional investors have recently modified their holdings of IPHA. Jane Street Group LLC purchased a new position in shares of Innate Pharma in the 4th quarter worth $162,000. OLD Mission Capital LLC purchased a new stake in Innate Pharma during the fourth quarter valued at $50,000. Finally, Millennium Management LLC purchased a new stake in Innate Pharma during the fourth quarter valued at $36,000. 0.16% of the stock is owned by institutional investors.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.